Background The use of direct oral anticoagulants (DOACs) is a convenient therapeutic
option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the …

Abstract Background Direct oral anticoagulants (DOACs) cause false positive lupus
anticoagulant (LA) results. We assessed the impact of DOAC-Stop, reversing in vitro effects …

Introduction Lupus anticoagulant (LA) investigation in patients on anticoagulant therapy is
problematic. Rivaroxaban in particular causes significant interference, prolonging both LA …

Abstract Background Direct oral anticoagulants (DOACs) interfere with lupus anticoagulant
(LAC) testing. DOAC‐Stop (D‐S) represents a preanalytical strategy to cope with this issue …

Objectives This study established the performance characteristics of DOAC-Remove for
neutralization of the effects of rivaroxaban and apixaban in lupus anticoagulant (LAC) …

Abstract Background DOAC Filter (DF) is a new device to overcome interference in lupus
anticoagulant (LAC) testing by direct oral anticoagulants (DOACs). Objectives We evaluated …

Laboratory diagnosis of lupus anticoagulant (LA) is based on prolongation in at least one
coagulation assay (diluted Russell's viper venom time–dRVVT or activated partial …

Objective Determination of lupus anticoagulants (LA) is an important, but still challenging
test in the diagnosis of antiphospholipid syndrome (APS). This is especially the case in …

We and others have previously highlighted the potential problems with testing of lupus
anticoagulants (LA) in patients on anticoagulant therapy, including most recently as related …

Non-vitamin K antagonist oral anticoagulants (NOAC), including rivaroxaban, apixaban or
dabigatran, regularly show relevant effects on coagulation tests, making the interpretation of …